Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease

Bibliography

• Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308–28; quiz 329
   PubMed Web of Science ®Google Scholar
• Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 2008;103:788-97
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Scheiman JM, Sadeghi S, et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol 2011;106:254-60
   PubMed Web of Science ®Google Scholar
• Ho KY. From GERD to Barrett’s esophagus: is the pattern in Asia mirroring that in the West? J Gastroenterol Hepatol 2011;26:816-24
   PubMed Web of Science ®Google Scholar
• Rubenstein JH, Chen JW. Epidemiology of gastroesophageal reflux disease. Gastroenterol Clin North Am 2014;43:1-14
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Rohof WO. Pathophysiology of gastroesophageal reflux disease. Gastroenterol Clin North Am 2014;43:15-25
   PubMed Web of Science ®Google Scholar
• Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837-47
   PubMed Web of Science ®Google Scholar
• Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996;38:649-54
   PubMed Web of Science ®Google Scholar
• Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992;33:118-24
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008;359:1700-7
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305
   PubMed Web of Science ®Google Scholar
• Bardou M, Martin J. Pantoprazole: from drug metabolism to clinical relevance. Expert Opin Drug Metab Toxicol 2008;4:471-83
   PubMed Web of Science ®Google Scholar
• Bardou M, Barkun AN, Hamza S, et al. Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients. Expert Opin Drug Metab Toxicol 2012;8:1199-208
   PubMed Web of Science ®Google Scholar
• Bardou M. Dexlansoprazole delayed release: pharmacotherapy of erosive esophagitis and GERD. Clin Med Insights 2011;3:291-300
   Google Scholar
• Saccar CL. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol 2009;5:1113-24
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006;23(Suppl 2):2-8
   PubMed Web of Science ®Google Scholar
• Schneider H, Van Rensburg C, Schmidt S, et al. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis. Digestion 2004;70:250-6
   PubMed Web of Science ®Google Scholar
• Keating GM, Figgitt DP. Intravenous esomeprazole. Drugs 2004;64:875-82; discussion 883
   PubMed Web of Science ®Google Scholar
• Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20
   PubMed Web of Science ®Google Scholar
• Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004;60:531-9
   PubMed Web of Science ®Google Scholar
• Rohss K, Wilder-Smith C, Naucler E, Jansson L. Esomeprazole 20 mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig 2004;24:1-7
   PubMed Web of Science ®Google Scholar
• Wilder-Smith CH, Rohss K, Bondarov P, et al. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. Aliment Pharmacol Ther 2004;20:1099-104
   PubMed Web of Science ®Google Scholar
• Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005;22(Suppl 3):20-4
   PubMedGoogle Scholar
• Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000;56:665-70
   PubMed Web of Science ®Google Scholar
• Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-7
   PubMed Web of Science ®Google Scholar
• Andersson T, Rohss K, Bredberg E, Hassan-Alin M. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001;15:1563-9
   PubMed Web of Science ®Google Scholar
• Omari T, Davidson G, Bondarov P, et al. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;45:530-7
   PubMed Web of Science ®Google Scholar
• Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol 2007;64:386-90
   PubMed Web of Science ®Google Scholar
• Bladh N, Blychert E, Johansson K, et al. A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. Clin Ther 2007;29:640-9
   PubMed Web of Science ®Google Scholar
• Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005;20:153-67
   PubMedGoogle Scholar
• Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-13
   PubMed Web of Science ®Google Scholar
• Lou HY, Chang CC, Sheu MT, et al. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism. Eur J Clin Pharmacol 2009;65:55-64
   PubMed Web of Science ®Google Scholar
• Kearns GL, Leeder JS, Gaedigk A. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect. Drug Metab Dispos 2010;38:894-7
   PubMed Web of Science ®Google Scholar
• Hunfeld NG, Touw DJ, Mathot RA, et al. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2012;35:810-18
   PubMed Web of Science ®Google Scholar
• Schwab M, Klotz U, Hofmann U, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005;78:627-34
   PubMed Web of Science ®Google Scholar
• Sjovall H, Bjornsson E, Holmberg J, et al. Pharmacokinetic study of esomeprazole in patients with hepatic impairment. Eur J Gastroenterol Hepatol 2002;14:491-6
   PubMed Web of Science ®Google Scholar
• Omari T, Lundborg P, Sandstrom M, et al. Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease. J Pediatr 2009;155:222-8
   PubMed Web of Science ®Google Scholar
• Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001;40:145-50
   PubMed Web of Science ®Google Scholar
• Flouvat B, Delhotal-Landes B, Cournot A, Dellatolas F. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993;36:467-9
   PubMed Web of Science ®Google Scholar
• Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28
   PubMed Web of Science ®Google Scholar
• Naesdal J, Andersson T, Bodemar G, et al. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986;40:344-51
   PubMed Web of Science ®Google Scholar
• Tjon JA, Pe M, Soscia J, Mahant S. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy 2013;33:956-71
   PubMed Web of Science ®Google Scholar
• Barron JJ, Tan H, Spalding J, et al. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr 2007;45:421-7
   PubMed Web of Science ®Google Scholar
• Davidson G, Wenzl TG, Thomson M, et al. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients. J Pediatr 2013;163:692-8. e691-692
   PubMed Web of Science ®Google Scholar
• Winter H, Gunasekaran T, Tolia V, et al. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr 2012;55:14-20
   PubMed Web of Science ®Google Scholar
• Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003;143:219-23
   PubMed Web of Science ®Google Scholar
• Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009;154:514-20. e514
   PubMed Web of Science ®Google Scholar
• Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr 2010;50:609-18
   PubMed Web of Science ®Google Scholar
• Gilger MA, Tolia V, Vandenplas Y, et al. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2008;46:524-33
   PubMed Web of Science ®Google Scholar
• Boulenc X, Djebli N, Shi J, et al. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite. Drug Metab Dispos 2012;40:187-97
   PubMed Web of Science ®Google Scholar
• Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993;69:655-9
   PubMed Web of Science ®Google Scholar
• Tolia V, Bishop PR, Tsou VM, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006;42:384-91
   PubMed Web of Science ®Google Scholar
• Gold BD, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007;45:520-9
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000;14:1249-58
   PubMed Web of Science ®Google Scholar
• Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65
   PubMed Web of Science ®Google Scholar
• Schmitt C, Lightdale CJ, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006;51:844-50
   PubMed Web of Science ®Google Scholar
• Lightdale CJ, Schmitt C, Hwang C, Hamelin B. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci 2006;51:852-7
   PubMed Web of Science ®Google Scholar
• Howden CW, Ballard ED III, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Investig 2002;22:99-109
   PubMed Web of Science ®Google Scholar
• Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005;21:455-63
   PubMed Web of Science ®Google Scholar
• Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21:739-46
   PubMed Web of Science ®Google Scholar
• Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol 2009;15:990-5
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006;24:743-50
   PubMed Web of Science ®Google Scholar
• Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol 2006;4:1452-8
   PubMed Web of Science ®Google Scholar
• Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927-35
   PubMed Web of Science ®Google Scholar
• Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: metropole study results. Aliment Pharmacol Ther 2003;17:333-41
   PubMed Web of Science ®Google Scholar
• Devault KR, Johanson JF, Johnson DA, et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006;4:852-9
   PubMed Web of Science ®Google Scholar
• Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005;22:803-11
   PubMed Web of Science ®Google Scholar
• Maton PN, Vakil NB, Levine JG, et al. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf 2001;24:625-35
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011;305:1969-77
   PubMed Web of Science ®Google Scholar
• Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol 2008;6:393-400
   PubMed Web of Science ®Google Scholar
• Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58:295-309
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association I, Clinical P. et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392-413. e1391-1395
   PubMed Web of Science ®Google Scholar
• Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000;14:1595-603
   PubMed Web of Science ®Google Scholar
• Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-40
   PubMed Web of Science ®Google Scholar
• Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006;4:50-6
   PubMed Web of Science ®Google Scholar
• Richter JE. Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications. Am J Gastroenterol 2000;95:368-73
   PubMed Web of Science ®Google Scholar
• Lee J, Anggiansah A, Anggiansah R, et al. Effects of age on the gastroesophageal junction, esophageal motility, and reflux disease. Clin Gastroenterol Hepatol 2007;5:1392-8
   PubMed Web of Science ®Google Scholar
• Pilotto A, Leandro G, Franceschi M; Ageing, Acid-Related Disease Study G. Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. Aliment Pharmacol Ther 2003;17:1399-406
   PubMed Web of Science ®Google Scholar
• Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos 2012;40:1698-711
   PubMed Web of Science ®Google Scholar
• Marsot A, Goirand F, Milesi N, et al. Interaction of thiopental with esomeprazole in critically ill patients. Eur J Clin Pharmacol 2013;69:1667-72
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148; e141-145
   PubMed Web of Science ®Google Scholar
• Frelinger AL III, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol 2012;59:1304-11
   PubMed Web of Science ®Google Scholar
• Moceri P, Doyen D, Cerboni P, Ferrari E. Doubling the dose of clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thromb Res 2011;128:458-62
   PubMed Web of Science ®Google Scholar
• Fernando H, Bassler N, Habersberger J, et al. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J Thromb Haemost 2011;9:1582-9
   PubMed Web of Science ®Google Scholar
• Harmsze AM, van Werkum JW, Taubert D, et al. Esomeprazole but not pantoprazole is associated with lower plasma concentrations of clopidogrel’s active metabolite. Ann Pharmacother 2011;45:542-3
   PubMed Web of Science ®Google Scholar
• Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010;31:810-23
   PubMed Web of Science ®Google Scholar
• Kashour T, Al-Tannir M, Bahamid R. Changing prescription pattern of omeprazole among patients receiving clopidogrel. Int Heart J 2014;55:93-5
   PubMed Web of Science ®Google Scholar
• Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos 2012;33:278-83
   PubMed Web of Science ®Google Scholar
• Thomas MR, Storey RF. Optimal management of antiplatelet therapy and proton pump inhibition following percutaneous coronary intervention. Curr Treat Options Cardiovasc Med 2012;14:24-38
   PubMedGoogle Scholar
• Lahner E, Annibale B, Delle Fave G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 2009;29:1219-29
   PubMed Web of Science ®Google Scholar
• Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006;354:1787-95
   PubMed Web of Science ®Google Scholar
• Corleto VD, Festa S, Di Giulio E, Annibale B. Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes 2014;21:3-8
   PubMed Web of Science ®Google Scholar
• Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011;106:1209-18; quiz 1219
   PubMed Web of Science ®Google Scholar
• Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012;344:e372
   PubMed Web of Science ®Google Scholar
• Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95
   PubMed Web of Science ®Google Scholar
• Buendgens L, Bruensing J, Matthes M, et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care 2014;29:696; e611-695
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53
   PubMed Web of Science ®Google Scholar
• Eom CS, Park SM, Myung SK, et al. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med 2011;9:257-67
   PubMed Web of Science ®Google Scholar
• Lee J, Youn K, Choi NK, et al. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. J Gastroenterol 2013;48:1016-22
   PubMed Web of Science ®Google Scholar
• Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010;25:2786-95
   PubMed Web of Science ®Google Scholar
• Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med 2010;170:765-71
   PubMed Web of Science ®Google Scholar
• Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012;107:1361-9
   PubMed Web of Science ®Google Scholar
• Administration FDA. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. 2011. Available from: http:/www.fdagov/drugs/drugsafety/postmarketdrugsafetyinformationforpateintsandproviders/ucm213206htm
   Google Scholar
• MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 2014;174:564-74
   PubMed Web of Science ®Google Scholar
• Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One 2012;7:e50836
   PubMed Web of Science ®Google Scholar
• Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012;10:264-71
   PubMed Web of Science ®Google Scholar
• Fiocca R, Mastracci L, Attwood SE, et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther 2012;36:959-71
   PubMed Web of Science ®Google Scholar
• Ahn JS, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol 2013;19:2560-8
   PubMed Web of Science ®Google Scholar
• Moraes-Filho JP, Pedroso M, Quigley EM, Group PS. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. Aliment Pharmacol Ther 2014;39:47-56
   PubMed Web of Science ®Google Scholar
• Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83
   PubMed Web of Science ®Google Scholar